An overview of the rare parotid gland cancer

Kimberley Ho; Helen Lin; David K. Ann; Peiguo G. Chu; Yun Yen

doi:10.1186/1758-3284-3-40

An overview of the rare parotid gland cancer

Kimberley Ho, Helen Lin, David K. Ann, Peiguo G. Chu, Yun Yen

Research output: Contribution to journal › Review article › peer-review

58 Citations (Scopus)

Abstract

Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

Original language	English
Article number	40
Journal	Head and Neck Oncology
Volume	3
Issue number	1
DOIs	https://doi.org/10.1186/1758-3284-3-40
Publication status	Published - Dec 1 2011

Keywords

Parotid gland cancer
endosomal sorting complexes required for transport
epidermal growth factor receptor
multi-vesicular bodies
salivary gland cancer
targeted therapeutics
vacuolar protein sorting-associated protein 4B
vascular endothelial growth factor

ASJC Scopus subject areas

Otorhinolaryngology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1758-3284-3-40

Cite this

@article{5f62692943cb40f88ab1481c77532001,

title = "An overview of the rare parotid gland cancer",

abstract = "Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.",

keywords = "Parotid gland cancer, endosomal sorting complexes required for transport, epidermal growth factor receptor, multi-vesicular bodies, salivary gland cancer, targeted therapeutics, vacuolar protein sorting-associated protein 4B, vascular endothelial growth factor",

author = "Kimberley Ho and Helen Lin and Ann, {David K.} and Chu, {Peiguo G.} and Yun Yen",

year = "2011",

month = dec,

day = "1",

doi = "10.1186/1758-3284-3-40",

language = "English",

volume = "3",

journal = "Head and Neck Oncology",

issn = "1758-3284",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - An overview of the rare parotid gland cancer

AU - Ho, Kimberley

AU - Lin, Helen

AU - Ann, David K.

AU - Chu, Peiguo G.

AU - Yen, Yun

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

AB - Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases. In addition to the disease's basic epidemiology and pathology, we review some current discoveries of its tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared. We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.

KW - Parotid gland cancer

KW - endosomal sorting complexes required for transport

KW - epidermal growth factor receptor

KW - multi-vesicular bodies

KW - salivary gland cancer

KW - targeted therapeutics

KW - vacuolar protein sorting-associated protein 4B

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=80052869608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052869608&partnerID=8YFLogxK

U2 - 10.1186/1758-3284-3-40

DO - 10.1186/1758-3284-3-40

M3 - Review article

C2 - 21917153

AN - SCOPUS:80052869608

SN - 1758-3284

VL - 3

JO - Head and Neck Oncology

JF - Head and Neck Oncology

IS - 1

M1 - 40

ER -

An overview of the rare parotid gland cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this